tirzepatide kidney disease 𧬠New data from the SUMMIT trial reveals that long-term (Zepbound) may significantly improve function in patients with obesity, chronic kidney (CKD), and heart failure with preserved ejection fraction ( tirzepatide acute kidney injury In
Description
While the medication helps lower blood sugar in people with diabetes, it could potentially cause blood sugar to drop too low in pregnant women
95% CI, 0.42 to 0.87
Results For Study 4 At the end of the 36-week open-label ZEPBOUND lead-in period, of the 670 randomized patients, 93% were on ZEPBOUND MTD of 15 mg weekly and 7% were on MTD of 10 mg weekly
This long-term data provides reassurance for patients and practitioners alike
This could worsen inflammation or introduce bacteria
